Anti-Human FOLR1 (folate receptor 1) (Mirvetuximab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mirvetuximab. Mirvetuximab (M9346A) is a monoclonal antibody that specifically targets Folate receptor 1 (FOLR1).

Folate receptor 1 (FOLR1), also known as folate receptor alpha (FRα), is a glycosylphosphatidylinositol-anchored glycoprotein essential for transporting folate into cells. Elevated FOLR1 levels are linked to poor prognosis in cancers such as breast cancer and endometrial carcinoma, making it a potential target for cancer therapy. It has also been investigated as a biomarker for cancer diagnosis and a target for delivering cytotoxic agents, particularly in cancers affecting women^1,2.

Mirvetuximab (M9346A) is an antibody-drug conjugate that targets folate receptor alpha (FRα), commonly overexpressed in cancers such as ovarian cancer. The initial phase III FORWARD I trial did not show significant benefits in FRα-positive tumors. However, subsequent studies focusing on patients with high FRα expression produced promising results. Consequently, the US FDA granted accelerated approval for Mirvetuximab in patients with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Mirvetuximab has demonstrated efficacy in reducing the risk of tumor progression or death compared to chemotherapy, providing a valuable treatment option for advanced or recurrent ovarian cancer³.

This research-grade biosimilar does not contain the drug conjugate.

While normally expressed on the apical surfaces of healthy epithelial tissues, FOLR1 is overexpressed in various solid tumors, including ovarian, breast, lung, and gastric cancers.

Folate and reduced folate derivates

1. Liu Y, Lian T, Yao Y. Biomarkers. 2020;25(5):367-374.
2. Ginter PS, McIntire PJ, Cui X, et al. Clin Breast Cancer. 2017;17(7):544-549.
3. G B, Rl C, I V, et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2024;34(4).
4. Mirvetuximab - Search Results - MyBioSource. Accessed October 5, 2024. https://www.mybiosource.com/search/mirvetuximab